Steve Bryson, PhD, science writer —

Tavneos (avacopan) will soon be available as an add-on treatment for adults in England, Wales, and Northern Ireland with severe, active granulomatosis polyangiitis (GPA) or microscopic polyangiitis (MPA), the two main types of ANCA vasculitis (AAV), following a decision by regulatory authorities. The National Institute for Health and…

Similar to neutrophils, immune monocyte cells play an essential role in kidney damage caused by ANCA-associated vasculitis (AAV), a study discovered. The pro-inflammatory function of monocytes was stimulated by the immune signaling protein CSF2, also called GM-CSF. Therapeutically targeting monocytes or CSF2 may be a potential new treatment strategy…

A subtype of antibody-producing B-cells was significantly higher in the bloodstream of ANCA-associated vasculitis (AAV) patients with active kidney involvement compared with those who were in remission and healthy individuals. These findings may help monitor disease progression, as well as provide insights into AAV development, the researchers noted. The…

Significantly high levels of the inflammatory protein pentraxin-3 (PTX3) were found in the bloodstream and urine of people with ANCA-associated vasculitis (AAV), particularly those with kidney involvement, a study revealed. Unlike C-reactive protein (CRP), a widely used inflammatory biomarker, PTX3 correlated with standard measures of AAV disease activity before…

A molecule called sulfatide is found at low levels in people with ANCA-associated vasculitis (AAV), and may indicate the presence of inflammation and a form of kidney damage that is associated with poor outcomes, a pilot study reports. Thus, sulfatide levels may be a useful biomarker for AAV, a…

People with ANCA-associated vasculitis (AAV) have a higher risk of cardiovascular disease, especially in the months immediately following AAV diagnosis, a population-based analysis found. “Our study demonstrates a key ‘high-risk window’ that should prompt careful monitoring for CV [cardiovascular] disease and aggressive risk factor reduction,” the scientists said. The…

The Japanese Ministry of Health, Labor, and Welfare (MHLW) has approved Tavneos (avacopan) for the treatment of microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA). The approval of this first-in-class therapy — for the two main forms of ANCA-associated vasculitis (AAV) — was granted to Kissei Pharmaceuticals, which…

A lower, 100 mg dose of Nucala (mepolizumab) is equally effective at treating eosinophilic granulomatosis with polyangiitis (EGPA) as the standard 300 mg dose, and leads to less frequent adverse events, or AEs, a large European study showed. These findings suggest that a lower monthly dose of Nucala…

ChemoCentryx has filed an amendment to its application seeking approval of avacopan, an investigational therapy for the treatment of ANCA-associated vasculitis (AAV). The filing addresses the issues raised by an advisory committee of independent medical experts during a recent meeting with the U.S. Food and Drug…

Using lower doses of prednisolone in combination with Rituxan (rituximab) resulted in similar rates of remission and fewer adverse events than Rituxan plus higher doses of the glucocorticoid in treating ANCA-associated vasculitis (AAV). Those were the findings of a Phase 4 clinical trial in Japan that examined the effects…